Abstract

The potential of radiolabelled phenylpiperazines as agents for the detection and therapy of tumours of neural crest origin was evaluated by in vitro pharmacological studies with human neuroblastoma cell lines [SK-N-SH and SK-N-BE(2C)], and in vivo by biodistribution measurements. The ability of phenylpiperazines: 4-phenyl-piperazine (PP), 1-carboxamidino-4-phenyl-piperazine (CAPP), [4-(3-chlorophenyl)-piperazine (mCPP), 4-(3-trifluoro methyl phenyl)-piperazine (TFMPP), and (1,1-dimethyl-4-phenyl)-piperazinium hydrochloride (DMPP) and chlorophenyl hydroxypiperidine [CP(OH)P], to inhibit MIBG uptake by neuroblastoma cells was determined by incubation with [125I]MIBG (0.1 microM) for 2 h in the presence of varying concentrations (10(-8)-10(-3) M) of ligand. For measuring uptake, cells were incubated with [125I]IPP (0.1 microM) and cell-associated radioactivity was measured at various times. Retention was studied by incubating cells in the presence of [125I]IPP (0.1 microM) for 2 h, followed by replacement with drug-free medium and determination of cell-bound radioactivity. Selectivity of [125I]IPP uptake was studied by inhibition studies with MIBG, DMI, 5HT and phenylpiperazines. The biodistribution of [125I]IPP was measured in normal rats at 0.083, 0.5, 1, 2 and 24 h (six animals per group). The IC50S (microM) for inhibition of [125I]MIBG uptake were: PP, 1.5; CPP, 2.5; CAPP, 2.5; DMPP, 5; CP(OH)P, 30 and TFMPP, 65. The rate of cellular uptake of [125I]IPP was greatest between 0 and 60 min and decreased after 60 min, similar to MIBG. After an initial rapid washout of approximately 50% of the radioactivity, retention remained constant for 3 h. The IC50S (microM) for inhibition of [125I]IPP uptake were: MIBG, 18-25; DMI, 0.6-1.5; 5HT, > 100; IPP, 1.8-2.5; CPP, 7.0-9.0 and TFMPP, > or = 20. The in vivo studies demonstrated a pattern of distribution similar to MIBG. The results demonstrate that phenylpiperazines display significant affinity for neuroblastoma with uptake and retention characteristics similar to MIBG.

Highlights

  • The results demonstrate that phenylpiperazines display significant affinity for neuroblastoma with uptake and retention characteristics similar to MIBG

  • The aims of this study were: (1) to evaluate the ability of selected phenylpiperazine derivatives to compete with MIBG uptake by cultured neuroblastoma cells; (2) to evaluate the uptake and retention of a model phenylpiperazine, namely, 4(3-['251]iodophenyl) piperazine, in cultured neuroblastoma cells; and (3) to compare the biodistribution of 4-(3['25I]iodophenyl) piperazine with [1251]MIBG in rats

  • All reagents were obtained as the highest available grade from commercial sources. 4-(3-chlorophenyl)-piperazine, 4-phenylpiperazine (PP), 4-(3-trifluoro methyl phenyl)-piperazine (TFMPP) (1,1-dimethyl-4-phenyl)-piperazinium hydrochloride (DMPP) and the piperidine derivative chlorophenyl hydroxypiperidine (CP(OH)P), desmethylimipramine (DMI) and serotonin (5HT) were obtained from Sigma Chemical Co. 1-Carboxamidino-4-phenylpiperazine (CAPP) was prepared according to previously described methods (Hanson, 1982)

Read more

Summary

Objectives

The aims of this study were: (1) to evaluate the ability of selected phenylpiperazine derivatives to compete with MIBG uptake by cultured neuroblastoma cells; (2) to evaluate the uptake and retention of a model phenylpiperazine, namely, 4(3-['251]iodophenyl) piperazine, in cultured neuroblastoma cells; and (3) to compare the biodistribution of 4-(3['25I]iodophenyl) piperazine with [1251]MIBG in rats

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.